AbbVie Inc.
AbbVie Inc. (ABBV)
Overview
AbbVie Inc. is a global biopharmaceutical company headquartered in North Chicago, Illinois, that discovers, develops, and markets medicines across immunology, oncology, neuroscience, eye care, and aesthetics. It operates in the health care sector and trades on the NYSE under the ticker ABBV. AbbVie was spun off from Abbott Laboratories in 2013 as a stand-alone research-based pharmaceutical company and has since grown into one of the largest drugmakers in the world, reporting record net sales of roughly $61.2 billion in fiscal 2025 (up about 8.6% year over year) and employing approximately 57,000 people across more than 70 countries. Its medicines reached an estimated 74 million patients globally in 2025, and its 2020 acquisition of Allergan added Botox and a major aesthetics business to its portfolio.
What They Do & How They Make Money
AbbVie's business model is that of a research-driven pharmaceutical company: it invests heavily in R&D and licensing/acquisition deals to develop patented drugs, then earns revenue by selling those medicines — often at premium prices protected by patents and regulatory exclusivity — to patients through health systems, physicians, pharmacies, and insurers. Its two newest flagship immunology drugs, Skyrizi and Rinvoq, treat autoimmune conditions such as psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis, and were developed largely to succeed AbbVie's earlier blockbuster Humira, whose U.S. patent protection expired in 2023 and which has since faced steep biosimilar competition and a rapid sales decline. Beyond immunology, AbbVie earns revenue from neuroscience drugs (migraine treatments Ubrelvy and Qulipta, the antipsychotic Vraylar, and Botox Therapeutic for chronic conditions like migraine and muscle spasticity), oncology drugs (Imbruvica and Venclexta for blood cancers), and its aesthetics franchise (Botox Cosmetic and Juvederm dermal fillers), which sells directly to physicians and medical spas for cosmetic procedures rather than through traditional insurance-reimbursed channels. Because branded drugs eventually lose patent protection and face generic or biosimilar competition, AbbVie's business model depends on continuously replenishing its pipeline through internal R&D and external deal-making (licensing and acquiring promising drugs and biotech companies) to offset revenue erosion from products going off-patent.
Business Segments
AbbVie does not report discrete profit-and-loss operating segments in the way a diversified industrial company does; instead, it reports revenue by therapeutic area/product category, which functions as its de facto segmentation. Based on fiscal 2025 results:
- Immunology (~50% of revenue, roughly $30.4 billion, up 14%): Led by Skyrizi ($17.6 billion, up nearly 50%) and Rinvoq ($8.3 billion, up 39%), which together have more than offset the continued decline of Humira (down to $4.5 billion, roughly a 49% drop as biosimilar competition intensified). This is by far AbbVie's largest and most important growth engine.
- Neuroscience (~18% of revenue, roughly $10.8 billion, up 20%): Includes Botox Therapeutic ($3.8 billion), the antipsychotic Vraylar ($3.6 billion), and the migraine drugs Ubrelvy and Qulipta (combined $2.3 billion), representing AbbVie's second-fastest-growing area.
- Oncology (~11% of revenue, roughly $6.7 billion, up 1.5%): Anchored by the blood cancer drugs Venclexta ($2.8 billion) and Imbruvica ($2.9 billion, down 14% amid competitive and generic pressure).
- Aesthetics (~8% of revenue, roughly $4.9 billion, down 6%): Botox Cosmetic ($2.6 billion) and Juvederm dermal fillers ($1.0 billion), a segment that has softened amid weaker discretionary consumer spending on cosmetic procedures, particularly in China.
- Other/Eye Care and remaining products: The balance of revenue comes from eye care and other legacy branded and established pharmaceutical products.
Competitors
AbbVie's competitive landscape differs by therapeutic area:
- Immunology: Johnson & Johnson (Stelara, Tremfya), Amgen (biosimilars and Otezla), Novartis (Cosentyx), Eli Lilly (Taltz, Omvoh), Bristol Myers Squibb (Sotyktu), and numerous biosimilar manufacturers now competing directly against Humira.
- Neuroscience: Biogen and Eisai (Alzheimer's), Teva and Lundbeck (migraine and CNS drugs), and Otsuka/Bristol Myers Squibb (Vraylar's antipsychotic competitors).
- Oncology: Bristol Myers Squibb, Johnson & Johnson, Merck, and AstraZeneca compete broadly across blood cancer and solid tumor therapies.
- Aesthetics: Galderma and Merz Aesthetics are AbbVie's most direct rivals in neurotoxins and dermal fillers, with Revance Therapeutics also competing in the neurotoxin space.
Competitive Position
AbbVie's central competitive strength is its ability to have successfully executed one of the pharmaceutical industry's most closely watched patent-cliff transitions: rather than seeing overall revenue collapse when Humira — once the best-selling drug in the world — lost patent exclusivity, AbbVie had already built and commercialized two successor immunology drugs, Skyrizi and Rinvoq, with differentiated efficacy and broader label indications, allowing the company to grow immunology revenue even as Humira sales fell by roughly half. This "Humira replacement" execution is widely regarded as a case study in successful pharmaceutical portfolio management and gives AbbVie continued credibility with investors and physicians. The company's scale, global commercial infrastructure, and diversified therapeutic footprint (immunology, neuroscience, oncology, and aesthetics) also reduce its dependence on any single drug or disease area going forward, and its aesthetics franchise (Botox) provides a distinctive, largely cash-pay revenue stream less exposed to government and insurer pricing pressure than its prescription drug business.
Key risks include continued pricing pressure from the U.S. Inflation Reduction Act (IRA), which allows Medicare to negotiate prices on selected high-spend drugs and could eventually affect AbbVie's key immunology products as they age; the eventual patent expiration and biosimilar/generic threats facing Skyrizi and Rinvoq later in the decade, following the same pattern that hit Humira; and continued softness in the aesthetics business tied to discretionary consumer spending, particularly in China, where cosmetic procedure demand has weakened. AbbVie also carries ongoing execution risk in replenishing its pipeline through R&D and M&A to sustain long-term growth once its current lead products mature, along with typical large-pharma risks around drug safety/regulatory setbacks, litigation (including past opioid-related litigation exposure tied to legacy Allergan products), and the general political and regulatory scrutiny facing U.S. drug pricing.